Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer

Annals of Oncology

Volumn 15, Issue 1, 2004, Pages 28-32

  Selvaggi, G ^a   Novello, S ^a   Torri, V ^b   Leonardo, E ^c   De Giuli, P ^c   Borasio, P ^c   Mossetti, C ^c   Ardissone, F ^c   Lausi, P ^c   Scagliotti, G V ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Prognostic factors; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 9144256014     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh011     Document Type: Article

References (39)

1. Wells A. The epidermal growth factor receptor (EGFR) - a new target in cancer therapy. Signal 2000; 1: 4-11.
2. Ullrich A, Schlessinger J. Signal transduction by receptor with tyrosine kinase activity. Cell 1990; 61: 203-212.
3. Brabender J, Danenberg KD, Metzger R et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-1855.
4. Pastorino U, Andreola S, Tagliabue E et al. Immunohistochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15: 2858-2865.
5. Rusch V, Klimstra D, Venkatyraman E et al. Overexpression of the epidermal growth factor receptor and its ligand TGF alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3: 515-522.
6. Volm M, Dring P, Wodrich W. Prognostic significance of the expression of c-fos, c-jun, and c-erbB1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol 1993; 119: 507-510.
7. Veale D, Ashcroft T, Marsch C et al. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987; 55: 513-516.
8. Fontanini G, De Laurentiis M, Vignati S et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998; 4: 241-249.
9. Ohsaki Y, Tanno S, Fujita Y et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000; 7: 603-607.
10. Reinmuth N, Brandt B, Kunze WP et al. Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2, erbB3 in non-small cell lung cancer. Eur Resp J 2000; 16: 991-996.
11. Selvaggi G, Scagliotti GV, Torri V et al. HER2/neu overexpression in patients with radically resected non-small cell lung carcinoma. Cancer 2002; 94: 2669-2674.
12. World Health Organization. Histological typing of lung tumors. Tumori 1981; 67: 253-272.
13. Mountain CF. The new international staging system for lung cancer. Surg Clin North Am 1987; 67: 925-935.
14. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
15. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J Clin 2002; 52: 23-47.
16. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
17. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-6565.
18. Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Investig 1984; 74: 647-651.
19. Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1994; 13: 1133-1137.
20. Fontanini G, Vignati S, Bigini D et al. Epidermal growth factor receptor (EGFr) in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995; 31: 178-183.
21. Piyathilake CJ, Frost AR, Manne U et al. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 2002; 8: 734-744.
22. Meert AP, Martin B, Delmotte P et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002; 20: 975-981.
23. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9-S15.
24. Magne N, Fischel JL, Dubeuil A et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumor cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 2002; 86: 1518-1523.
25. Rusch V, Baselga J, Cordon-Cardo C et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53: 2379-2385.
26. Pfeiffer P, Clausen PP, Andersen K, Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185-HER-2 in patients with systemically untreated non-small cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996; 74: 86-91.
27. Gorgoulis V, Aninos D, Mikou P et al. Expression of EGF, TGF alpha and EGFR in squamous cell lung carcinomas. Anticancer Res 1992; 12: 1183-1187.
28. Cox G, Vyberg M, Melgaard B et al. Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int J Cancer 2001; 92: 480-483.
29. Hirsch FR, Varella-Garcia M, Franklin WA et al. Evaluation of HER2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002; 86: 1449-1456.
30. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970.
31. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19: S32-S40.
32. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000; 6: 2349-2355.
33. O'Byrne KJ, Cox G, Swinson D et al. Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer 2001; 34: S83-S89.
34. Garcia de Palazzo IE, Adams GP, Sundareshan P et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993; 53: 3217-3220.
35. Voldborg BR, Damstrup L, Spang-Thomsen M et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997; 8: 1197-1206.
36. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the erbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000; 77: 25-79.
37. Sirotnak FM, Zakowski MF, Miller VA et al. Efficacy of cytotoxic agents against human tumour xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-4892.
38. Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20: 3a (Abstr 7).
39. Magnè N, Fischel JL, Dubreuil A et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa'). Br J Cancer 2002; 86: 1518-1523.